论文部分内容阅读
目的分析孟鲁司特治疗小儿咳嗽变异性哮喘的应用效果及临床优势。方法 88例小儿咳嗽变异性哮喘患儿,应用随机数字表法分为治疗组和对照组,各44例。对照组患儿应用布地奈德雾化吸入治疗,治疗组在对照组基础上加用孟鲁司特治疗。对两组临床效果及安全性进行分析。结果治疗组总有效率为95.45%,高于对照组的81.82%(P<0.05);治疗组的咳嗽消失时间为(6.42±2.51)d,肺部哮鸣音消失时间为(5.07±1.54)d,均短于对照组的(11.89±2.77)、(8.93±2.69)d(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。两组不良反应未经干预均自行缓解。结论孟鲁司特治疗小儿咳嗽变异性哮喘的效果好,能够快速缓解临床症状,促进患儿康复,同时无明显不良反应,值得推广应用。
Objective To analyze the effect and clinical advantage of montelukast in the treatment of children with cough variant asthma. Methods A total of 88 children with cough variant asthma were randomly divided into treatment group and control group with 44 cases in each group. Control children with budesonide inhalation therapy, the treatment group in the control group based on the use of montelukast treatment. The clinical effects and safety of the two groups were analyzed. Results The total effective rate of the treatment group was 95.45%, which was higher than that of the control group (81.82%, P <0.05). The cough disappearance time was (6.42 ± 2.51) d and the duration of lung wheeze disappearance was (5.07 ± 1.54) d were shorter than that of the control group (11.89 ± 2.77) and (8.93 ± 2.69) days, respectively (P <0.05). The incidence of adverse reactions in the two groups, the difference was not statistically significant (P> 0.05). Two groups of adverse reactions were relieved without intervention. Conclusion Montelukast treatment of pediatric cough variant asthma is effective, can quickly relieve clinical symptoms and promote the recovery of children, without significant adverse reactions, it is worth promoting the application.